WS
HARP

Wedbush Securities’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Wedbush Securities’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,382
Closed -$235K – 1012
2020
Q3 		$235K Buy
+1,382
New +$199K 0.02% 714

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities's HARP Position: Q4 2020 in Review

Wedbush Securities sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2020, closing a stake of 1,382 shares — an estimated $235K sold.

Wedbush Securities first reported a position in HARP in Q3 2020 and held it in 1 quarter. The position peaked at $235K in Q3 2020. 77 funds tracked by Wall St. Rank hold HARP as of Q4 2020.

  • Wedbush Securities reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 1,382 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $235K.
  • Wedbush Securities first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Harpoon Therapeutics, Inc. Common Stock position peaked at $235K in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.